Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public by merging with a Cormorant-sponsored SPAC.

The merger agreement announced Friday is with Helix Acquisition Corp. II, a SPAC sponsored by affiliates of Cormorant Asset Management. When the deal closes, the combined company will take the ...